Cargando…

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by early metastasis, late detection, and poor prognosis. Progress towards effective therapy has been slow despite significant efforts. Novel treatment approaches are desperately needed and autophagy, an evolutionary conse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raufi, Alexander G., Liguori, Nicholas R., Carlsen, Lindsey, Parker, Cassandra, Hernandez Borrero, Liz, Zhang, Shengliang, Tian, Xiaobing, Louie, Anna, Zhou, Lanlan, Seyhan, Attila A., El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670090/ https://www.ncbi.nlm.nih.gov/pubmed/34916936 http://dx.doi.org/10.3389/fphar.2021.751568

Ejemplares similares

Targeting the Integrated Stress Response in Cancer Therapy
por: Tian, Xiaobing, et al.
Publicado: (2021)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics
por: Louie, Anna D., et al.
Publicado: (2021)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer
por: Raufi, Alexander G., et al.
Publicado: (2023)

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies
por: Liguori, Nicholas R., et al.
Publicado: (2021)

Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

The role of p53 in anti-tumor immunity and response to immunotherapy
por: Carlsen, Lindsey, et al.
Publicado: (2023)

Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation
por: Carlsen, Lindsey, et al.
Publicado: (2022)

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53
por: Hernandez Borrero, Liz, et al.
Publicado: (2021)

Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
por: Schnipper, Julie, et al.
Publicado: (2020)

Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy
por: Hofschröer, Verena, et al.
Publicado: (2021)

Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors
por: Chang, Wen-I, et al.
Publicado: (2022)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients
por: Leaf, Sofia, et al.
Publicado: (2021)

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
por: Carlsen, Lindsey, et al.
Publicado: (2022)

Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells
por: Zhou, Lanlan, et al.
Publicado: (2020)

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection
por: Zhou, Lanlan, et al.
Publicado: (2020)

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs
por: Huntington, Kelsey E., et al.
Publicado: (2021)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
por: Zhao, Shuai, et al.
Publicado: (2021)

Identifying Drug Targets in Pancreatic Ductal Adenocarcinoma Through Machine Learning, Analyzing Biomolecular Networks, and Structural Modeling
por: Yan, Wenying, et al.
Publicado: (2020)

An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
por: Xiao, Zhijun, et al.
Publicado: (2021)

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
por: Seeber, Andreas, et al.
Publicado: (2020)

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
por: Sahin, Ilyas, et al.
Publicado: (2021)

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC)
por: Le Bozec, Antoine, et al.
Publicado: (2023)

Riproximin Exhibits Diversity in Sugar Binding, and Modulates some Metastasis-Related Proteins with Lectin like Properties in Pancreatic Ductal Adenocarcinoma
por: Sagini, Micah N., et al.
Publicado: (2020)

The role of epithelial-mesenchymal transition and autophagy in pancreatic ductal adenocarcinoma invasion
por: Yang, Jian, et al.
Publicado: (2023)

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
por: Tian, Xiaobing, et al.
Publicado: (2021)

Integrated analysis of Dendrobium nobile extract Dendrobin A against pancreatic ductal adenocarcinoma based on network pharmacology, bioinformatics, and validation experiments
por: Xu, Xiaoqing, et al.
Publicado: (2023)

Actin gamma 1 is a critical regulator of pancreatic ductal adenocarcinoma
por: Tang, Yichen, et al.
Publicado: (2021)

Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
por: Weng, Ningna, et al.
Publicado: (2022)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b95ha48949dunkjtf5ss2tm70p